Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eisai Ltd ADR (OP:ESALY)

N/A UNCHANGED
Last Price Updated: 3:59 PM EST, Jan 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eisai Ltd ADR

< Previous 1 2 3 4 5 6 7 Next >
News headline image
US Stock Futures Down Ahead Of Fed Speakers, Economic Data ↗
Pre-open movers U.S. stock futures traded lower in early pre-market trade on Wednesday after closing mostly lower on Tuesday. The S&P 500 index dropped deeper into a bear market after hitting a fresh... 
Via Benzinga
News headline image
Alzheimer's Progression Slowed Down By Biogen's New Drug In Late-Stage Study: Analyst Sees 25% Upside For Stock ↗
Biogen, Inc. (NASDAQ: BIIB) and Eisai Co. Ltd. (OTC: ESALY) announced late Tuesday positive results from a late-stage study of their Alzheimer’s treatment candidate. 
Via Benzinga
News headline image
Merck's Keytruda Combo Trial Fails To Meet Primary Goal In Liver Cancer ↗
 
Via Benzinga
News headline image
Citi Is Bullish On This Large Pharma Stock On Upcoming Data Readout From Diabetes Candidate ↗
Citi has increased peak risk-adjusted Eli Lilly And Co's (NYSE: LLY) tirzepatide forecasts (diabetes/ obesity/NASH) to more than $25 billion (previously $15 billion, consensus of around $16 billion).  
Via Benzinga
News headline image
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Merck's Two Keytruda Combo Cancer Trials Miss Primary Goal ↗
 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Biogen Pops After Eisai Asks FDA To Approve A New Alzheimer's Treatment ↗
Eisai finished submitting its application for lecanemab, another anti-amyloid drug. 
Via Investor's Business Daily
News headline image
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Biogen, Eisai Amend Their Alzheimer's Drug Marketing Pact ↗
 
Via Benzinga
News headline image
Eisai - Biogen Seek Accelerated Approval For Their Second Alzheimer's Drug ↗
 
Via Benzinga
News headline image
The Daily Biotech Pulse: SELLA In-licenses Oncology Asset, Merck's Pneumococcal Vaccine Review Extended, Arc Biopharma COVID Drug Flunks Mid-Stage Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Biogen, Eisai Unveil New Data On Another Alzheimer's Candidate, Lecanemab ↗
In the partnership that spawned aducanumab, Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) have  
Via Benzinga
News headline image
FDA Approves Second Indication For Merck's Keytruda In Endometrial Cancer ↗
The  
Via Benzinga
News headline image
News-Filled Day ↗
The price of oil fell to below $100/oz on the prospect of lower demand from the PRC. 
Via Talk Markets
News headline image
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Hopes For A Peace Accord ↗
The winner today was BioNTech up 14.89% on hopes for new sales for the Covid-19 variant. 
Via Talk Markets
News headline image
The Daily Biotech Pulse: Ocugen Faces Regulatory Setback, vTv CEO Quits, Biogen-Eisai Make Headway With Second Alzheimer's Antibody Treatment In Japan ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Merck's Keytruda Evaluated In Combination With Microbiome Therapeutic In... 
Via Benzinga
News headline image
The Ruble Is Rubble ↗
MSCI says Russian companies are 
Via Talk Markets
News headline image
Merck-Eisai's Keytruda/Lenvima Combo Scores Japanese Approval For Kidney Cancer Setting ↗
The Japanese Ministry of Health, Labour, and Welfare (MHLW) has approved Merck & Co Inc's (NYSE: MRK) Keytruda/Lenvima combo therapy for radically... 
Via Benzinga
News headline image
Dampening Exuberance ↗
The bond sell-off halted today but the Fed's plans mean this will resume. 
Via Talk Markets
News headline image
Weakened Tech Stocks ↗
There was a 0.5% rise in UK interest rates, twice what had been anticipated and moreover early, because of inflation risks. 
Via Talk Markets
News headline image
The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Eisai Announces Publication Of Positive Data On Lenvima-Keytruda Combo In... 
Via Benzinga
News headline image
CMS Proposes Coverage Of Biogen's Alzheimer's Drug, With Conditions Apply ↗
The Centers for Medicare & Medicaid Services (CMS) released a proposed national coverage determination for Medicare to cover drugs that target amyloid for mild... 
Via Benzinga
News headline image
Christmas is Coming ↗
November saw a very modest increase in consumer spending, 0.6%. That means we are probably making up for it this month. 
Via Talk Markets
News headline image
A Bit Of Good News ↗
US growth figures for Q3 were up from forecasts of 2.1% at 2.3% but well down from the prior quarter level of 6.7%. 
Via Talk Markets
News headline image
Biogen Outlines Aduhelm's Confirmatory Trial Plans, Data Expected In 2026 ↗
Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) are looking to get initial data from the FDA-mandated confirmatory trial for its Alzheimer’s... 
Via Benzinga
News headline image
Uncertain Times ↗
The UK inflation rate last month was 5.1%, not a good omen. 
Via Talk Markets
News headline image
Europe Approves Merck-Eisai's Keytruda/Lenvima Combo Therapy For Endometrial Carcinoma ↗
The European Commission has approved a combination of Merck & Co Inc's (NYSE: MRK) Keytruda plus Eisai Co Ltd's (OTC: ESALY) Lenvima for... 
Via Benzinga
News headline image
Why Are Biogen Shares Gaining Today? ↗
​​​​​​Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease. Related:... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.